Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
EZmito: a simple and fast tool for multiple mitogenome analyses.
Cucini C, Leo C, Iannotti N, Boschi S, Brunetti C, Pons J, Fanciulli PP, Frati F, Carapelli A, Nardi F. Cucini C, et al. Among authors: iannotti n. Mitochondrial DNA B Resour. 2021 Mar 19;6(3):1101-1109. doi: 10.1080/23802359.2021.1899865. Mitochondrial DNA B Resour. 2021. PMID: 33796755 Free PMC article.
Correction: Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
Munster P, Iannotti N, Cho DC, Kirkwood JM, Villaruz LC, Gibney GT, Hodi FS, Mettu NB, Jones M, Bowman J, Smith M, Lakshminarayanan M, O'Day S. Munster P, et al. Among authors: iannotti n. Cancer Res Commun. 2024 Mar 13;4(3):785. doi: 10.1158/2767-9764.CRC-24-0133. Cancer Res Commun. 2024. PMID: 38477691 Free PMC article. No abstract available.
Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy.
Lombardi A, Villa S, Colaneri M, Scaglione G, Bai F, Varisco B, Bono V, Vena A, Dentone C, Russo C, Tettamanti M, Renisi G, Viero G, Azzarà C, Mantero M, Peyvandi F, Bassetti M, Marchetti G, Muscatello A, Nobili A, Gori A, Bandera A; “COVID 19 NETWORK”. Lombardi A, et al. J Infect Public Health. 2024 Mar;17(3):467-473. doi: 10.1016/j.jiph.2023.12.026. Epub 2024 Jan 17. J Infect Public Health. 2024. PMID: 38262085 Free article.
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
Munster P, Iannotti N, Cho DC, Kirkwood JM, Villaruz LC, Gibney GT, Hodi FS, Mettu NB, Jones M, Bowman J, Smith M, Lakshminarayanan M, O'Day S. Munster P, et al. Among authors: iannotti n. Cancer Res Commun. 2023 Dec 19;3(12):2572-2584. doi: 10.1158/2767-9764.CRC-22-0461. Cancer Res Commun. 2023. PMID: 38115208 Free PMC article. Clinical Trial.
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy.
Weiss SA, Sznol M, Shaheen M, Berciano-Guerrero MÁ, Couselo EM, Rodríguez-Abreu D, Boni V, Schuchter LM, Gonzalez-Cao M, Arance A, Wei W, Ganti AK, Hauke RJ, Berrocal A, Iannotti NO, Hsu FJ, Kluger HM. Weiss SA, et al. Among authors: iannotti no. Clin Cancer Res. 2024 Jan 5;30(1):74-81. doi: 10.1158/1078-0432.CCR-23-0475. Clin Cancer Res. 2024. PMID: 37535056 Free PMC article. Clinical Trial.
Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients.
Lombardi A, Viero G, Villa S, Biscarini S, Palomba E, Azzarà C, Iannotti N, Mariani B, Genovese C, Tomasello M, Tonizzo A, Fava M, Valzano AG, Morlacchi LC, Donato MF, Castellano G, Cassin R, Carrabba M, Muscatello A, Gori A, Bandera A. Lombardi A, et al. Among authors: iannotti n. Biomedicines. 2023 May 26;11(6):1540. doi: 10.3390/biomedicines11061540. Biomedicines. 2023. PMID: 37371635 Free PMC article.
Safety Profile and Outcomes of Early COVID-19 Treatments in Immunocompromised Patients: A Single-Centre Cohort Study.
Biscarini S, Villa S, Genovese C, Tomasello M, Tonizzo A, Fava M, Iannotti N, Bolis M, Mariani B, Valzano AG, Morlacchi LC, Donato F, Castellano G, Cassin R, Carrabba M, Muscatello A, Gori A, Bandera A, Lombardi A. Biscarini S, et al. Among authors: iannotti n. Biomedicines. 2022 Aug 18;10(8):2002. doi: 10.3390/biomedicines10082002. Biomedicines. 2022. PMID: 36009549 Free PMC article.
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Subbiah V, Iannotti NO, Gutierrez M, Smith DC, Féliz L, Lihou CF, Tian C, Silverman IM, Ji T, Saleh M. Subbiah V, et al. Among authors: iannotti no. Ann Oncol. 2022 May;33(5):522-533. doi: 10.1016/j.annonc.2022.02.001. Epub 2022 Feb 14. Ann Oncol. 2022. PMID: 35176457 Free article. Clinical Trial.
Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor.
Hrinczenko B, Iannotti N, Goel S, Spigel D, Safran H, Taylor MH, Bennouna J, Wong DJ, Kelly K, Verschraegen C, Bajars M, Manitz J, Ruisi M, Gulley JL. Hrinczenko B, et al. Among authors: iannotti n. Future Oncol. 2022 Apr;18(11):1333-1342. doi: 10.2217/fon-2021-0930. Epub 2022 Feb 11. Future Oncol. 2022. PMID: 35144482 Free PMC article. Clinical Trial.
54 results